Stürzebecher J, Prasa D, Hauptmann J, Vieweg H, Wikström P
Klinikum der Friedrich-Schiller-Universität Jena, Erfurt, Germany.
J Med Chem. 1997 Sep 12;40(19):3091-9. doi: 10.1021/jm960668h.
Thrombin is the key enzyme in the blood coagulation system, and inhibitors of its proteolytic activity are of therapeutic interest since they are potential anticoagulants. The most potent inhibitor of the benzamidine type is N alpha-[(2-naphthylsulfonyl)glycyl]-4-amidinophenylalanylpiperid ide (NAPAP). However, NAPAP and other benzamidine derivatives do not show favorable pharmacological properties; above all, they have very low systemic bioavailability after oral administration. The goal of designing new compounds was to obtain potent inhibitors with improved pharmacokinetic properties. Piperazide derivatives of 3-amidinophenylalanine as the key building block were synthesized. The piperazine moiety opened the possibility to introduce quite different substituents on the second nitrogen using common synthetic procedures. Some of the newly synthesized compounds are potent inhibitors of thrombin and offer an approach to study structure-function relationships for inhibition of thrombin and related enzymes and for the improvement of their pharmacokinetic properties.
凝血酶是血液凝固系统中的关键酶,其蛋白水解活性抑制剂具有治疗意义,因为它们是潜在的抗凝剂。最有效的苯甲脒类抑制剂是Nα-[(2-萘磺酰基)甘氨酰]-4-脒基苯丙氨酰哌啶(NAPAP)。然而,NAPAP和其他苯甲脒衍生物并未表现出良好的药理学特性;最重要的是,它们口服给药后的全身生物利用度非常低。设计新化合物的目标是获得具有改善药代动力学特性的强效抑制剂。合成了以3-脒基苯丙氨酸为关键结构单元的哌嗪衍生物。哌嗪部分使得利用常规合成方法在第二个氮原子上引入截然不同的取代基成为可能。一些新合成的化合物是凝血酶的强效抑制剂,为研究凝血酶及相关酶抑制的结构-功能关系以及改善其药代动力学特性提供了一种方法。